Sunovion Pharmaceuticals announced that the Food and Drug Administration (FDA) approved Kynmobi® (apomorphine hydrochloride), a new sublingual medication for fast relief of OFF symptoms of Parkinson’s disease (PD). Apomorphine acts as a dopamine agonist, mimicking the effects of dopamine in the brain. It was previously only available as Apokyn, an injectable medication that provides as-needed fast relief of OFF time that might occur between scheduled doses of Levodopa. This new formulation of apomorphine is a sublingual strip which is placed under the tongue when patients start experiencing OFF time. Kynmobi can be used up to five times a day and is available in five different doses (10mg, 15 mg, 20 mg, 25 mg, 30 mg).
In a recently-published clinical trial, Kynmobi was shown to improve motor scores by 11 points, 30 minutes after use of a sublingual strip, as compared to 3.5 points after use of the placebo. For a detailed discussion of motor fluctuations and OFF time please view this webinar.
Kynmobi is not yet available in pharmacies, but.Sunovion anticipates it will be available in September 2020.
APDA welcomes this new addition to the arsenal of medications available to physicians to treat the symptoms of PD. We are excited about the renewed hope for PD patients that this progress brings.